COVID-19 With Convalescent Plasma

Completed

• Conditions: COVID-19 Convalescent Plasma Treatment
• Interventions: Biological: convalescent plasma

• Registration Number: NCT04616976
• Lead Sponsor: Southeast University, China

Brief Summary

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Primary Completion: 2020-02-29
• Status Verified: 2020-11
• Study Completion: 2020-11-01
• Study First Submitted: 2020-11-01
• Study First Submitted QC: 2020-11-03
• Last Update Submitted: 2020-11-03
• Study First Posted: 2020-11-05
• Last Update Posted: 2020-11-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

1. > 18 years of age;
2. laboratory-confirmed diagnosis of COVID-19;
3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula[HFNC], noninvasive mechanical ventilation [NIV], and invasive mechanical ventilation [IMV]).

Exclusion Criteria

• no

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
convalescent plasma therapy group	convalescent plasma	the patients received convalescent plasma therapy

Primary Outcome Measures

Name	Time	Method
28-day mortality	28 days	the mortality from ICU admission to 28 days after admission

Secondary Outcome Measures

Name	Time	Method
SARS-CoV-2 negative conversion rate	up to 60 days	SARS-CoV-2 viral shedding

Trial Locations

Locations (1)

Zhongda Hospital, Southeast University; 🇨🇳 Nanjing, Jiangsu, China